Birmingham, ALABAMA1 Active Studies

Non-Alcoholic Fatty Liver Disease Clinical Trials in Birmingham, ALABAMA

Find 1 actively recruiting non-alcoholic fatty liver disease clinical trials in Birmingham, ALABAMA. Connect with local research sites and explore new treatment options.

1
Active Trials
1
Sponsors
1,050
Enrolling

Recruiting Non-Alcoholic Fatty Liver Disease Studies in Birmingham

About Non-Alcoholic Fatty Liver Disease Clinical Trials in Birmingham

Non-alcoholic fatty liver disease (NAFLD/MASLD) is a condition where excess fat builds up in the liver without significant alcohol consumption. It is the most common liver disease in Western countries. Management includes weight loss, exercise, and treatment of associated metabolic conditions.

There are currently 1 non-alcoholic fatty liver disease clinical trials recruiting participants in Birmingham, ALABAMA. These studies are seeking a combined 1,050 participants. Research is being sponsored by 89bio, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Non-Alcoholic Fatty Liver Disease Clinical Trials in Birmingham — FAQ

Are there non-alcoholic fatty liver disease clinical trials in Birmingham?

Yes, there are 1 non-alcoholic fatty liver disease clinical trials currently recruiting in Birmingham, ALABAMA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Birmingham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Birmingham research site will contact you about next steps.

Are clinical trials in Birmingham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Birmingham studies also compensate for your time and travel.

What non-alcoholic fatty liver disease treatments are being tested?

The 1 active trials in Birmingham are testing new therapies including novel drugs, biologics, and treatment approaches for non-alcoholic fatty liver disease.

Data updated March 2, 2026 from ClinicalTrials.gov